Assessing the Impact of a Multidimensional Approach and an 8-Component Bundle in Reducing Incidences of Ventilator-Associated Pneumonia Across 35 Countries in Latin America, Asia, the Middle East, and Eastern Europe
Victor Daniel Rosenthal,Zhilin Jin,Ruijie Yin,Suneeta Sahu,Prasad Rajhans,Mohit Kharbanda,Pravin K. Nair,Shakti Bedanta Mishra,Rajesh Chawla,Rajalakshmi Arjun,Kavita Sandhu,Camilla Rodrigues,Reshma Dongol,Sheila Nainan Myatra,Mat Nor Mohd-Basri,Tai Chian-Wern,Arpita Bhakta,Ider Bat-Erdene,Subhash P. Acharya,Gustavo Andres Alvarez,Lina Alejandra Aguilar Moreno,Katherine Gomez,Luisa Fernanda da Jimenez-Alvarez,Claudia Milena Henao-Rodas,Sandra Liliana Valderrama-Beltran,Maria Adelia Zuniga-Chavarria,Guadalupe Aguirre-Avalos,Blanca Estela Hernandez-Chena,Alejandro Sassoe-Gonzalez,Mary Cruz Aleman-Bocanegra,Maria Isabel Villegas-Mota,Daisy Aguilar De Moros,Alex Castaneda-Sabogal,Nilton Yhuri Carreazo,Safaa Alkhawaja,Hala Mounir Agha,Amani El-Kholy,Mohammad Abdellatif-Daboor,Oguz Dursun,Emel Okulu,Merve Havan,Dincer Yildizdas,Suna Secil Ozturk Deniz,Ertugrul Guclu,Sona Hlinkova,Aamer Ikram,Lili Tao,Abeer Aly Omar,Naheed Elahi,Ziad A. Memish,Michael M. Petrov,Lul Raka,Jaroslaw Janc,George Horhat-Florin,Eduardo Alexandrino Medeiros,Estuardo Salgado,Lourdes Duenas,Monica Coloma,Valentina Perez,Eric Christopher Brown
DOI: https://doi.org/10.1016/j.jcrc.2023.154500
IF: 4.298
2024-01-01
Journal of Critical Care
Abstract:Background: Ventilator associated pneumonia (VAP) occurring in the intensive care unit (ICU) are common, costly, and potentially lethal. Methods: We implemented a multidimensional approach and an 8-component bundle in 374 ICUs across 35 low and middle-income countries (LMICs) from Latin-America, Asia, Eastern-Europe, and the Middle-East, to reduce VAP rates in ICUs. The VAP rate per 1000 mechanical ventilator (MV)-days was measured at baseline and during intervention at the 2nd month, 3rd month, 4-15 month, 16-27 month, and 28-39 month periods. Results: 174,987 patients, during 1,201,592 patient-days, used 463,592 MV-days. VAP per 1000 MV-days rates decreased from 28.46 at baseline to 17.58 at the 2nd month (RR = 0.61; 95% CI = 0.58-0.65; P < 0.001); 13.97 at the 3rd month (RR = 0.49; 95% CI = 0.46-0.52; P < 0.001); 14.44 at the 4-15 month (RR = 0.51; 95% CI = 0.48-0.53; P < 0.001); 11.40 at the 16-27 month (RR = 0.41; 95% CI = 0.38-0.42; P < 0.001), and to 9.68 at the 28-39 month (RR = 0.34; 95% CI = 0.32-0.36; P < 0.001). The multilevel Poisson regression model showed a continuous significant decrease in incidence rate ratios, reaching 0.39 (p < 0.0001) during the 28th to 39th months after implementation of the intervention. Conclusions: This intervention resulted in a significant VAP rate reduction by 66% that was maintained throughout the 39-month period.